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Abstract
In a recent National Research Council document, new strategies for risk assessment were 
described to enable more accurate and quicker assessments.(1) This report suggested that 
evaluating individual responses through increased use of biomonitoring could improve dose-
response estimations. Identification of specific biomarkers may be useful for diagnostics or risk 
prediction as they have the potential to improve exposure assessments. This paper discusses 
systems biology, biomarkers of effect, and computational toxicology approaches and their 
relevance to the occupational exposure limit setting process.
The systems biology approach evaluates the integration of biological processes and how 
disruption of these processes by chemicals or other hazards affects disease outcomes. This type of 
approach could provide information used in delineating the mode of action of the response or 
toxicity, and may be useful to define the low adverse and no adverse effect levels. Biomarkers of 
effect are changes measured in biological systems and are considered to be preclinical in nature. 
Advances in computational methods and experimental -omics methods that allow the simultaneous 
measurement of families of macromolecules such as DNA, RNA, and proteins in a single analysis 
have made these systems approaches feasible for broad application.
The utility of the information for risk assessments from -omics approaches has shown promise and 
can provide information on mode of action and dose-response relationships. As these techniques 
evolve, estimation of internal dose and response biomarkers will be a critical test of these new 
technologies for application in risk assessment strategies. While proof of concept studies have 
been conducted that provide evidence of their value, challenges with standardization and 
harmonization still need to be overcome before these methods are used routinely.
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INTRODUCTION
Currently, little toxicity data exist for most of the 82,000 chemicals used in the United 
States, which greatly hampers risk assessment and management activities.(2, 3) In addition, 
it is rare for workers or the general public to be exposed to only to a single compound, but 
rather they are exposed to complex mixtures that may have additive, synergistic, or 
antagonistic actions. The complexity of exposure scenarios and lack of data make risk 
management decisions difficult and time consuming.
The systems biology approach is based on consideration of normal biological processes 
(including pathways leading to effects and homeostatic and adaptive responses) and how 
chemicals disrupt those processes.(4, 5) This type of approach would provide integrated 
information that could be used in delineating the mode(s) (MOA) of action of the adverse 
response or toxicity.(6, 7) Different doses can produce widely different responses in an 
organism. Some of the responses are of no consequence to the health or viability of the 
organism, others may be beneficial (e.g., antioxidant), and others are toxic.(8)
Biomarkers have been defined by the National Academy of Sciences (NAS) as measurable 
changes in a biological system or organism or measured alterations in structure or function.
(9) Biomarkers may be indicative of exposure, response or effect, and susceptibility and can 
be used to monitor exposures and a wide variety of responses ranging from abnormal 
development to early disease indicators.(9, 10)
Occupational exposures are mainly by inhalation or through the dermal route, while the 
primary route for general environmental exposures is by ingestion. Route of exposure may 
affect the level of internal dose and therefore the toxicity. Biomarker measurements are an 
aggregate of all exposure pathways. One benefit of early response biomarkers is in their 
interpretation within the context of integrated systems models, which connect these 
biomarkers to adverse outcomes of regulatory concern. Advances in computational 
methods(11) and experimental -omics methods that allow the simultaneous measurement of 
families of macromolecules such as DNA, RNA, and proteins in a single analysis(12) have 
made these systems approaches feasible for broad application in both pharmaceutical 
discovery(11) and environmental risk assessment.(6) The promise is that information on 
hazard characterization, dose response and risk characterization can be generated by -omics 
methods and used in risk assessments.(7, 13)
This manuscript focuses on systems biology, biomarkers of effect/response, and 
computational toxicology approaches and their relevance to the occupational exposure limit 
(OEL) setting process. A glossary of key terms relating to this topic is provided in Table I 
and acronyms are defined in Table II.
Key points of emphasis covered in this manuscript include:
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• Many drivers exist for increased reliance on systems biology approaches that are 
pushing changes in health risk assessment methods, including for OEL setting.
• Practical long-term implications of such approaches are many, including decreased 
uncertainty in OELs through improved understanding of biological responses at 
lower levels of chemical exposure.
• Current methods and tools for consideration of effect biomarkers and the 
relationship with the toxic MOA within the framework of systems biology are 
being used and applied in OEL setting via proof of concept studies.
CURRENT EFFORTS ON EARLY RESPONSE BIOMARKERS AND RISK 
ASSESSMENT
Some efforts have been initiated in the global community to revise the way that risk 
assessments are conducted or to speed the data flow into risk assessments. The European 
Registration, Evaluation, Authorisation, and Restriction of Chemicals (REACH) program 
seeks to determine the risk of thousands of chemicals that are produced in quantities greater 
than 10 tons/year.(14) Derived No Effect Levels are required for all chemicals that are 
classified as a health hazard. Traditional toxicity testing is unsustainable and unethical under 
this paradigm, because of the large number of animals that would be needed and the 
associated high cost.(15) Efforts to establish a sustainable strategy for toxicity testing in the 
United States were accelerated when the National Research Council (NRC) defined a vision 
of toxicity testing in the 21st century that called for greater use of in vitro testing, 
computational system approaches, and a reduction of expensive animal testing.(3, 16) In the 
NRC strategy, toxicity testing would evaluate specific perturbations in identified pathways 
rather than by direct evidence of adverse effects; therefore, risk assessments would be 
revised to incorporate this new information.(17) These new technologies could be performed 
faster and cheaper and evaluate toxicity of a larger number of concentrations.
Shortly after the NRC report on toxicity testing,(3) a separate NRC committee published 
recommendations on the use of toxicogenomic technologies and the need for more 
predictive toxicity testing for incorporation into risk assessments.(1) Improvements in cross 
species extrapolation, identification of vulnerable or sensitive populations, determination of 
life stage effects, investigation of mechanisms of action, and refinement of exposure 
assessments are all potential uses for toxicogenomic data.(1)
Computational toxicology was the subject of a National Academy of Sciences Standing 
Committee on Use of Emerging Science for Environmental Health Decisions meeting in 
September 2009. The field of computational toxicology has emerged in an effort to build 
predictive models from biomarker of effect data generated by omics technologies.(18) 
Computational toxicology identifies trends and patterns in biomarker and chemistry datasets.
(19) These models use chemical characterization to predict fate and transport as well as 
hazard identification. Computational toxicology also seeks to describe ways through which 
chemicals cause toxicity by developing computational tools that better utilize high 
throughput screening (HTS) and toxicogenomics data for hazard prediction. This includes 
models at varying levels of biological complexity, from relatively simple statistical 
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models(20–22) to advanced dose-response and virtual tissue models.(23, 24) The field of 
computational toxicology has rapidly expanded to include many more applications than 
HTS, which is still an evolving research area and in need of validation. Other applications 
are being utilized such as data mining the literature, in vitro- in vivo extrapolations, 
quantitative structure activity relationships, in silico models and use of National Health and 
Nutrition Examination Survey biomonitoring data for identification of populations at special 
risk of toxicity.(25–27)
In 2009, a third NRC publication was released that examined the EPA risk assessment 
process and how to practically improve it to assess human health risks.(28) Two main areas 
of risk analysis were evaluated, technical analysis and utility of risk. Technical analysis is 
how scientific information is generated and used so that more accurate risk characterizations 
can be obtained. Utility of risk examines the relevance of the risk assessments for making 
risk management decisions. A key recommendation was to improve the upfront design of 
risk assessments to make them more useful to answer risk management needs. In particular, 
the report emphasized the importance of problem formulation in determining the scope of 
the assessment, issues needing consideration, and options so that the risk assessment can 
support risk management decision-making. The report also noted the importance of 
characterizing and communicating uncertainty and variability and of placing greater 
emphasis on the evaluation of risk from cumulative exposure scenarios.
The EPA has initiated a program [http://www.epa.gov/risk/nexgen/] to evaluate the use of 
HTS, computational toxicology, and systems modeling for risk assessment and risk 
management for environmental exposures and the general population, though not necessarily 
occupational exposures.(29) The vision is for a tiered system that provides risk estimates on 
the basis of available data as well as a formal means for recommending chemicals for higher 
tier investigation.
ROLE OF BIOMARKERS IN OCCUPATIONAL RISK ASSESSMENT
A major aim of biomarker research is to develop and validate biomarkers that reflect 
specific exposures or are quantitatively linked to adverse outcomes in humans to enable their 
use in risk prediction. Biomarkers have a number of advantages over “apical endpoints” 
typically observed in in vivo toxicology studies.
Recent advances in biomedical technology have provided powerful tools to identify new 
biomarkers. -Omics technologies are increasingly being used and have brought capabilities 
to investigate adverse responses, underlying toxicity mechanisms, and key toxicity pathways 
that have the potential to be used in risk assessment.(30–32)
Environmental exposures can directly or indirectly cause alterations in gene expression at 
either the transcriptional (gene expression) or the translational level (proteomics). 
Development of gene expression profiles using oligonucleotide microarrays provides a view 
of perturbations at the transcript level and helps identify specific genes, pathways or 
networks that are specific to the toxic end point of interest.(33) Identifying appropriate 
biomarkers can be difficult because interpretation of global gene expression changes is 
challenging as such changes may reflect nonspecific responses or overlapping/interacting 
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molecular processes. The use of toxicogenomics data along with other types of supportive 
toxicological data has been considered for hazard characterization. Recent studies have 
shown that benchmark dose estimates, based on gene expression omics data, for non-cancer 
and cancer apical endpoints can be practically applied.(22, 34)
Determination of internal dose is important in risk assessment and provides highly relevant 
information that is more closely associated with disease response than external exposure 
estimates.(35) The capability of -omics technologies to generate information that can be 
used for internal dose estimation and response markers will be important in their use in risk 
assessment. Epigenetics effects may also have an important role in the development of 
disease. For example, gene silencing, which is the interruption or suppression of the 
expression of a gene at transcriptional or translational levels, can occur with 
hypermethylation of DNA.(36) Biomarkers of hypermethylation of DNA may be useful as 
early cancer detectors and therefore may have utility in risk assessments.
Although biomarkers have been identified using -omics technologies, there is no well-
established standardized application of these technologies in using biomarkers in risk 
assessment. Involvement of multiple molecular pathways in disease as in systems biology 
creates complex data analysis/interpretation challenges in validating associations between 
outcomes and sets of biomarkers.
The concept of the exposome, which encompasses all exposures over a lifetime, has the 
potential to improve risk assessment.(37) The exposome will rely on -omics or other high 
throughput techniques for the identification of biomarkers of exposure and effect. Multiplex 
profiling (metabolomics, proteomics, and transcriptomics) is now being used along with 
complementary assays for the most comprehensive and informative views of biological 
systems.(38) The exposome has the potential to offer more comprehensive exposure data 
that can be used to develop more accurate exposure profiles to improve risk assessments.
Most common chronic diseases involve the interaction of multiple exposures and biological 
pathways that ultimately lead to disease. System biology approaches have been used to 
study a variety of diseases such as epilepsy and metabolic syndrome and exposures such as 
particulate matter found in air pollution.(39–41) However, systems biology and how 
different biological processes may interact with one another to result in disease needs to be 
better understood to be useful in risk assessment.
The NRC(3) identified several strategies to use biomarkers of effect to extrapolate dose and 
evaluate dose response. Physiological-based pharmacokinetic (PBPK) modeling can 
describe the relationship between external exposure and the internal dose (e.g., blood or 
tissue concentration of a toxicant) that simulate the toxicity pathways of a chemical. PBPK 
models can also be used to estimate an external dose (i.e., the relevant real world exposure) 
that would correspond to the doses used in in vitro and in vivo test systems, as well as in 
dose-response models to predict the environmental exposure needed to elicit a toxic 
response.(3) Extrapolating in vitro dose-response data to predict responses in vivo has been a 
challenge because the doses applied in vitro have typically been much higher than cells in 
vivo (e.g., in the lungs) would experience even at occupational exposures.(42) An example 
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of one approach is a range of in vitro doses (~0.2–68 μg/ml) that was proposed based on 
estimates of the equivalent doses to human lung cells after either 24-hr or a 45-year working 
lifetime exposure to 1 mg/m3 of poorly soluble particles.(42) Uncertainty about how well in 
vitro studies predict responses in in vivo systems includes the effect of dose rate and the role 
of other cells and processes in determining the in vivo response.(43) An example of in vitro 
assays that show predictive trends of in vivo dose-response relationships is for biomarkers of 
inflammation in lung epithelial cell cultures and acute pulmonary inflammation in rats.(44, 
45)
Establishing a dose of concern is a primary goal of risk assessment. Several approaches that 
use an internal dose have also been described, including internal dose measures such as 
biological exposure indices(46) and biomonitoring equivalents.(47) Additionally, no 
observed effect levels and benchmark dose estimates can be applied for both internal and 
external dose measures.(48–50) These dose estimates may be used as points of departure to 
estimate exposures associated with lower (or presumed no) disease risk.
Genotype-exposure interactions are particularly important for occupational and 
environmental diseases. Environmental and occupational triggers may interact with genetic 
factors to initiate the disease process or influence the clinical outcomes including time to 
onset, severity of the response, or dose. There has been little effort in incorporating genetic 
information into the risk assessment process, although the advantage of such data in 
improving accuracy has been discussed.(51–53)
Currently, the default approach for addressing inter-individual variation in susceptibility for 
threshold effects is to apply a 10X uncertainty factor.(54, 55) Note that this factor is not 
intended to cover the entire range of human variability. Instead, this factor addresses the 
difference between a “safe dose” estimate in the general population and the “safe dose” 
estimate in the population of interest.(56) While the default size of the inter-individual factor 
is 10X, smaller or larger factors may be applied if supported by the available data, resulting 
in refined estimates of human variability. Criteria for the use of data to support other factors 
have been developed by the International Programme on Chemical Safety (IPCS).(57) 
Biomarkers can play a critical role in describing the distribution of responses to a specified 
dose. This concept is illustrated in Figure 3, in which the distribution (e.g., the biomarker for 
a physiologically important response) is shifted in the susceptible populations or life stages, 
resulting in a bi- or multi-modal overall distribution. The shape of the distribution for a 
given biomarker would depend on how it is distributed in the population (e.g., whether 
associated with specific gene alleles or results from multiple causes).
METHODS AND APPROACHES
Risk Assessment Methods and Issues
The goal of human health risk assessment is to predict the likelihood of adverse health 
effects before they manifest in a population. Different types of studies can provide 
information that has utility in risk assessments. Epidemiologic studies are important for the 
assessment of toxic effects directly in humans because no interspecies extrapolation is 
needed. Such studies are also important in estimating population-based, exposure-
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attributable risks. The most important challenges related to epidemiological studies are the 
difficulties in precise estimation of exposure, existence of confounding variables such as 
other exposures and considerable inter-individual variation including genetic make-up, 
physiological, nutritional, and lifestyle differences. Such studies are also costly and time 
consuming and have limitations in characterizing dose-response relationships, causal 
mechanisms, and extrapolating to low doses in risk assessment.(58, 59)
Extrapolations from animal studies to humans are confounded by a number of issues, 
including species-specific differences in uptake and response, homogeneity of test animals 
as compared to heterogeneity of human populations and short-term testing as compared to 
complex lifetime exposure, as well as uncertainties due to gaps in the available data. 
Extrapolation is further complicated by levels and routes of exposure, as these factors can 
differ greatly between animal models and real-life exposure scenarios. With regard to 
interspecies extrapolation, several factors must be considered, such as dose normalization 
for the differences in body size, metabolic rate, variability in toxicokinetics of the chemical 
and sensitivity of the target for toxicity. Occupationally-exposed populations have 
considerable physiological and genetic variability in such factors as metabolic capacity and 
in toxicity response.
Efforts have been undertaken to harmonize dose-response relationships for cancer and non-
cancer endpoints(60) focusing on MOA as the basis for selecting dose-response models and 
determining extrapolation approaches.(61, 62) In general, the default science policy choice 
based on MOA assumes that a threshold would not exist for substances that interact directly 
with DNA. This is based on the idea that damage to one DNA molecule could be fixed as a 
mutation and clonally expand to cancer or result in other effects, such as developmental 
toxicity. MOAs that do not involve direct DNA reactivity (e.g., cytotoxicity leading to either 
necrosis or to regenerative cell proliferation and cancer) are generally considered to have 
biological response thresholds, due to the existence of repair and redundant cellular 
processes.(63) However, when data are available that provide strong evidence for alternative 
modes of action, these data may replace default assumptions in risk assessment and OEL 
derivation. For example, NIOSH(64) used evidence concerning a secondary genotoxic MOA 
(via persistent inflammation) to inform selection of the nonlinear (but also non-threshold) 
dose-response models used to estimate the working lifetime risk of lung cancer from 
inhalation exposure to the poorly-soluble particulate titanium dioxide (TiO2).
There has been considerable discussion in the risk assessment community recently 
concerning the observation of non-threshold behavior for chemicals that do not interact with 
DNA.(28, 65, 66) A threshold response for a given agent may be difficult to detect in a 
population (e.g., a statistical dose-response model may not be able to exclude zero as a 
possible threshold dose), even if the MOA evidence indicates a threshold is plausible. 
Reasons for observing non-threshold behavior in a population for non-carcinogens include 
variability in individual threshold responses or exposures that contribute to an existing 
disease process.(67, 68) Rhomberg et al.(66) suggested some alternative explanations, such 
as measurement error at low exposures in epidemiology studies, for not detecting a threshold 
in human studies when a threshold is observed in animal studies. Additionally, the 
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observation of a threshold may be influenced by factors including variability and sample 
size in both animal studies and epidemiology studies.
Risk estimates based on extrapolating high-dose animal studies to humans may be 
particularly sensitive to assumptions about the MOA and shape of dose-response 
relationships including threshold/non-threshold assumptions. Thus, there may be 
considerable uncertainty in extrapolation from animal studies when the doses are 
considerably higher than those relevant to OEL development (e.g., if the MOA that occurs at 
a high dose is not relevant to that occurring at a much lower dose). Additional uncertainty 
may occur from temporal extrapolations, which could result in over- or under-estimation of 
the risk of long-term exposure.(69, 70) Even when the MOA is known, statistical arguments 
cannot resolve the uncertainty in low-dose extrapolation, and so science policy choices (e.g., 
default approach of linear low dose extrapolation for carcinogens in the absence of strong 
evidence indicating otherwise) are needed in risk assessment.
One of the advantages of using biomarkers of effect is that they can help to reduce the need 
for extrapolation, allowing instead evaluation of effects in the dose range of interest and in 
the species of interest (e.g., when human cells are tested in vitro). Under ideal situations, the 
MOA is used to identify appropriate biomarkers, which are then evaluated sufficiently close 
to the dose range of interest, so that mathematical curve fitting can be used to more directly 
estimate risk, rather than relying on the cruder approaches of linear extrapolation (assuming 
no threshold) or uncertainty factors (assuming a threshold response).
The use of precursor effect data or biomarkers of early effect is gaining increased scrutiny 
for use in risk assessments.(22, 71) A challenge is that many of these biomarkers lack 
validation.(72) The basis for extrapolation between the biomarker and the toxicological 
outcome needs to be established so that a dose associated with a low risk of an adverse 
health effect can be estimated.(71)
Direct Dose-Response Using Early Effects Data
The analysis of -omic dose-response studies has traditionally utilized analysis of variance 
(ANOVA) approaches together with pair-wise comparisons between dose groups and the 
corresponding control.(73, 74) The ANOVA identifies genes that are significantly altered as 
a function of dose while the pair-wise comparisons identify genes that are significantly 
altered between specific dose pairs. The ANOVA approach for analyzing -omic dose-
response studies is analogous to the methods used to define lowest observed adverse effect 
levels (LOAEL) or no observed adverse effect levels (NOAEL) for other toxicological 
endpoints. For applying -omic dose-response data to chemical risk assessment, the 
traditional ANOVA approach faces several challenges in that dose spacing and the 
experimental sample size can have a dramatic impact on the final NOAEL and LOAEL, and 
the approach does not account for variability in the estimate of the dose-response or the 
slope of the dose-response curve.
To utilize -omic dose-response data within the existing risk assessment paradigm, 
benchmark dose (BMD) methods have been used to fit a statistical model to the dose-
response data and to identify a dose that causes a defined change in the endpoint of interest.
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(22, 34, 75) The application of the BMD method provides several advantages including 
better use of dose-response information, more appropriate reflection of experimental sample 
sizes, and the lack of constraint to experimental doses. (76) In this analysis, the dose and 
individual gene response data are fit with the standard set of statistical models used in BMD 
analysis. A single model is selected for each gene based on fit, modeling complexity, and 
the BMD and associated lower confidence limit (BMDL).
To allow investigators to interpret the -omic data and provide context for the observed BMD 
values, public and commercial databases are used to group genes into functional processes 
and signalling pathways.(77, 78) The choice of database depends on the context required for 
interpreting the -omic dose response study. For certain studies, a pathway-based analysis 
may provide a better understanding of the underlying perturbations in the signaling networks 
while in other studies, an analysis focused on cellular-processes may provide better linkage 
with the phenotypic effects of the chemical. The BMD and BMDL values for the individual 
genes are summarized to represent the general behavior of the process or signaling pathway 
as a function of dose. In most cases, the mean or median BMD and BMDL are sufficient to 
capture the general dose-related perturbation of the category or pathway. In certain studies, 
the transcriptional BMD values for specific cellular biological processes and pathways 
showed a high degree of correlation with traditional non-cancer and cancer-related apical 
BMD values.(22, 79) Many of the correlated processes and pathways had been implicated in 
non-cancer and cancer disease pathogenesis. Subsequent studies have demonstrated a high 
degree of correlation between transcriptional BMD values for the most sensitive pathway 
response and traditional non-cancer and cancer-related apical BMD values.(13)
Early effects data can provide evidence about the MOA and the shape of the dose-response 
relationship for disease development. Epigenetic effects may alter down-stream responses 
and outcomes. However, to most effectively use early response and systems biology data in 
risk assessment and OEL derivation, predictive models are needed to link the early response 
with the probability of developing the frank effect (conditional on the early effect).
An example MOA involving early responses and frank effect is persistent lung inflammation 
associated with development of cancer.(80) This effect has also been observed in animals 
related to inhaled, poorly-soluble particles(81) including TiO2. The MOA for rat lung cancer 
from inhaled poorly soluble particles is generally considered to involve persistent pulmonary 
inflammation, which causes oxidative DNA damage.(81) Driscoll et al.(82) observed an 
increased mutation frequency in the hypoxanthine-guanine phosphoribosyl transferase gene 
(hprt mutations are detrimental lesions caused by oxidative damage to DNA) in alveolar 
type II cells from rats treated with a high mass dose (100 mg/kg) of fine-sized TiO2 or other 
types of poorly-soluble particles. In vitro, hprt mutation frequency was also increased in an 
alveolar epithelial cell line (RLE-6TN) following co-incubation with inflammatory cells 
(alveolar macrophages and neutrophils) derived from bronchoalveolar lavage fluid from 
particle-treated rats.(82) Addition of catalase (an enzyme which protects cells against 
oxidative damage) to these co-incubations inhibited the increase in hprt mutations. These 
studies support a role of inflammatory cell-derived oxidants in particle-associated 
mutagenesis.
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In risk assessment and development of recommended exposure limits for fine and ultrafine 
TiO2, NIOSH(64) used statistical models of animal dose-response data for lung cancer and 
pulmonary inflammation to estimate the working lifetime risks. On the basis of a secondary 
genotoxic mechanism, prevention of persistent lung inflammation would be expected to 
prevent lung cancer by that mechanism. However, evaluation of the rat subchronic 
inflammation data did not show evidence of a threshold (although the dose-response 
relationship was nonlinear). Rat- and human-based excess risk estimates for lung cancer 
from working lifetime exposures to inhaled poorly-soluble particles were compared. The 
particles evaluated include those for which long-term dose-response data are available in 
both species, i.e., coal dust, carbon black, titanium dioxide, silica, and diesel exhaust 
particulate. The excess risk estimates derived from the rat data were generally lower than 
those derived from the human studies, and none of the rat- and human-based risk estimates 
were significantly different (all p-values>0.05).(83) Given the limited data available to 
quantitatively evaluate the relationship between inflammation and lung cancer in rats or 
humans, NIOSH derived the Recommended Exposure Limits on the basis of rat dose-
response data for lung tumors. NIOSH estimated the human-equivalent, 8-hr time-weighted 
average concentrations associated with <1/1000 excess risk of lung cancer over a working 
lifetime, derived from the nonlinear dose-response models fit to the rat data.(64)
Biologically-Based Dose Response (BBDR) Models
Risk estimates that rely on default assumptions may be uncertain to the extent that the true 
relationships differ from those assumptions. This uncertainty arises from the limited data 
that are available to inform the selection of the dose-response models and the assumptions 
used in interspecies and low-dose extrapolations. Risk estimates on the basis of default 
assumptions may overestimate the risk for a population because the default approaches are 
intended to be conservative in the absence of chemical-specific data.(84) They may also 
underestimate risk in other cases (e.g., if greater individual variability exists than accounted 
for in the default assumptions).(85, 86)
By utilizing measurements of biological pathway perturbations, uncertainties in the target 
tissue dose across species and the influence of exposure routes may be decreased, resulting 
in more reliable risk assessments.(84) An advantage of a BBDR model is that, by describing 
key steps in the development of toxic effects, alternative mechanisms of action can be 
evaluated and compared to the data, to test hypotheses and evaluate the importance of 
specific assumptions. BBDR models also have the advantage of directly predicting the 
response at doses of interest, avoiding the threshold/non-threshold dichotomy, but they may 
require assumptions about the connections between dose and key events. These models can 
also incorporate inter-individual susceptibility and confounders such as existing diseases and 
background exposures.(65) Although BBDR models have a number of advantages, a key 
issue in their use is the uncertainties associated with the parameters used in the model, as 
well as the substantial sensitivity of the model results to the assumptions regarding the 
underlying mathematical form for intermediate steps in the mechanism of action.(87) 
However, identification of biomarkers corresponding to these intermediate steps would 
provide an opportunity to directly address these assumptions and reduce the uncertainty of 
key parameters. Verification of BBDR model predictions, as well as incorporation of 
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population-based distributions of parameter values, may be needed for wider acceptance of 
these models in risk assessment and development of OELs. The International Programme on 
Chemical Safety(88) guidance on use of physiologically-based pharmacokinetic (PBPK) 
models in risk assessment provides a template to facilitate understanding of models by risk 
assessors; a key consideration is comparing the uncertainties of the PBPK/BBDR model 
with those of the default approach.
Biologically-informed empirical dose-response modeling provides a bridge between strictly 
empirical models and full BBDRs. Such approaches are analogous perhaps to 
compartmental pharmacokinetic models, but can incorporate pharmacodynamic data using 
biomarkers. Like the compartmental pharmacokinetic models, the biologically-informed 
empirical dose-response models incorporate some chemical-specific data, but include 
empirical curve-fitting. The goal of such analytical methods is to improve the qualitative and 
quantitative description of the biological processes determining the shape of the dose-
response curve, without investing the resources needed to develop and verify a BBDR 
model. An advantage of these approaches is the use of quantitative data on early events 
(biomarkers) to extend the overall dose-response curve to lower doses using biology, rather 
than being limited to the default choices of linear extrapolation or uncertainty factors. Using 
biomarkers to extend the dose-response curve towards the dose region of interest also offers 
the potential for better description of the dose-response relationship of chemicals with a 
MOA that includes contributions from both DNA-reactive and non-DNA reactive 
components.
Allen et al.(71) developed such a model as a proof of concept for predicting risk of lung 
cancer given persistent lung inflammation from chronic inhalation of TiO2 in rats. A series 
of cause and effect functions, fit using a likelihood estimation approach, were utilized to 
describe the relationships between successive key events leading to the ultimate tumor 
response. This approach was used to evaluate a hypothesized pathway for progression from 
a biomarker of exposure (lung burden), through several intermediate potential biomarkers of 
effect, to the clinical effect of interest (lung tumor production).
Another approach to biologically-informed empirical dose-response modeling was 
demonstrated by Hack et al.,(89) who used a Bayesian network model to integrate exposure 
biomarkers to conduct an exposure-dose-response assessment for acute myeloid leukemia 
resulting from exposure to benzene. The network approach was used to evaluate and 
compare individual biomarkers and quantitatively link the biomarkers along the exposure-
disease continuum. This work provides a quantitative approach for linking changes in 
biomarkers of effect both to exposure information and to changes in disease response. Such 
linkage can provide a scientifically valid point of departure that incorporates precursor dose-
response information without being dependent on the difficult issue of a definition of 
adversity for precursors.
More classical mathematical approaches also have the potential for linking biomarkers to 
adverse effects. For example, the Hill model describes the biology of a chemical binding to a 
receptor, a key event in many receptor-mediated MOAs. Budinsky et al.(90) used the Hill 
model to compare the dose-response for aryl hydrocarbon receptor-mediated CYP1A1 and 
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CYP1A2 messenger RNA induction and enzyme activity in rat and human hepatocytes 
exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin, 2,3,4,7,8-pentachlorodibenzofuran, or 
2,3,7,8-tetrachlorodibenzofuran. In an extended analysis of genome-wide transcriptomic 
data from the same experiment, BMD analysis of the gene expression changes showed an 
average 18-fold cross-species difference in potency among differentially expressed 
orthologs and similar differences were observed for signaling pathways.(91) The data were 
used to support the conclusion that humans are less sensitive than rats to these aryl 
hydrocarbon receptor-dependent end points and to support the use of a modified uncertainty 
factor for extrapolating between rats and humans.
More general approaches to empirical dose-response modeling are incorporated in standard 
modeling methods where the mathematical form used for empirical curve-fitting is based on 
the presumed shape of the biological response. Thus, for example, probit modeling is 
typically used for modeling lethality data. Similarly, a multistage model has been used for 
tumor modeling, based on the multi-stage model for cancer. In an example of modifying the 
standard choice based on biology, Dourson et al.(92) used the probit model to describe the 
dose-response for thyroid tumors in rats orally exposed to acrylamide. This choice was 
based on both improved empirical model fit compared to the multistage model, and the 
observation that the shape of the probit model better reflected (compared with the default 
linear extrapolation approach) the mixed MOA of DNA reactivity at low doses and growth 
stimulation at the higher doses tested in the animal bioassay.
CONCLUSIONS
Advantages and Limitations
Several key advantages to the use of biomarkers in risk assessments exist. Biomarkers are 
used to identify the MOA and can support the MOA in risk assessments rather than relying 
on general default approaches. Additionally, biomarkers can be used to characterize inter-
individual variability by helping to ensure that sensitive populations are identified and 
adequately addressed in the assessments and to reduce uncertainty in the extrapolation of 
animal data to humans.(53, 93) Another advantage of biomarkers is hypotheses are tested at 
doses relevant to human exposures. One ultimate goal of the use of biomarkers is to extend 
the dose-response curve to the range (or near the range) of the exposures of interest. This 
would allow one to use the biomarker data more directly to evaluate dose-response, without 
having to go to default approaches of linear or nonlinear extrapolation. Such data could be 
used to establish more appropriate OELs to protect individuals who are at high risk. Systems 
biology and MOA approaches will also lead to new hypotheses and ways of thinking about 
chemical risk assessments and hence move the entire field of risk assessment forward.
While early biomarkers of effect have great promise, many limitations and challenges need 
to be overcome before early effect biomarkers can be reliably used. The whole field of 
computational toxicology and systems biology is still evolving and results have not been 
validated in human populations. Appropriate interpretation and validation of biomarker 
results is lacking.
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Special Issues in Applying These Approaches for OEL Setting
Developing OELs on the basis of early effects dose-response data means that more sensitive, 
relevant endpoints could be targeted for prevention. If these biomarkers can be validated to 
ensure they represent an adverse effect, it may be possible to reverse a deleterious exposure 
before the disease has progressed. These precursor events (i.e., detected using a biomarker) 
might be preclinical but could be associated with an increased susceptibility to develop the 
disease effect. Setting OELs to prevent early adverse effects may help to prevent material 
impairment of health and functional capacity as a result of workplace exposure. However, a 
challenge is to determine the linkage between early effects, which may not yet constitute 
material impairment of health and functional capacity, and the later adverse outcomes.
Since the risk of preclinical responses have not been well-defined with respect to what those 
biomarkers to health, this presents a challenge in how to utilize early effects data in a 
standardized, harmonized risk assessment strategy across agents and cancer and non-cancer 
endpoints, as recommended by the NRC.(28) The use of BBDR models to quantitatively 
link early preclinical changes to apical endpoints of regulatory concern may mitigate this 
problem in the future.
Standardization is an important issue in the use of biomarkers, although the issue is not 
unique to the biomarker-based risk assessments. In an approach based on the NOAEL/
LOAEL with uncertainty factors, the NOAEL may be based on a range of different 
responses or severity of response at the corresponding LOAEL. This severity of the endpoint 
may be addressed in the magnitude of the uncertainty factor applied to the LOAEL, but this 
is a relatively crude approach. One of the advantages of the BMDL is that it is based on a 
response level, but differences in severity of the endpoint can still lead to inconsistencies.
Early biological effects using a systems biology approach and computational toxicology 
efforts offer great promise for the future of risk assessment. Information on these effects can 
be generated using HTS providing needed information quicker and cheaper than 
conventional animal testing. Proof of concept studies in computational toxicology provide 
early evidence of their promise in utilizing early biomarkers in establishment of dose.(22, 
34) However, challenges such as standardization and validation still need to be overcome 
before these methods are used in routine risk assessments.
Acknowledgments
The authors would like to acknowledge Dr. Andrew Maier for his contribution and thoughtful insight in the areas of 
systems biology and risk assessment. Funding for Russell Thomas’s contribution to this document was provided by 
the American Chemistry Council’s Long Range Research Initiative.
References
The utility of genetic and epigenetic information in occupational risk assessment
1. NRC (National Research Council). Applications of Toxicogenomic Technologies to Predictive 
Toxicology and Risk Assessment. Washington, D.C: The National Academies Press; 2007. 
2. U.S. Government Accounting Office. [Accessed January 7, 2013] Chemical Regulation: Options 
Exist to Improve EPA’s Ability to Assess Health Risks and Manage its Chemical Review Program. 
2005. (http://www.gao.gov/new.items/d05458.pdf)
DeBord et al. Page 13













3. NRC (National Research Council). Toxicity Testing in The 21st Century: A vision and a Strategy. 
Washington, D.C: The National Academies Press; 2007. 
4. Kitano H. Computational systems biology. Nature. 2002; 420(6912):206–10. [PubMed: 12432404] 
5. Kohl P, Crampin EJ, Quinn TA, et al. Systems biology: an approach. Clin Pharmacol Ther. 2010; 
88(1):25–33. [PubMed: 20531468] 
6. Edwards SW, Preston RJ. Systems biology and mode of action based risk assessment. Toxicol Sci. 
2008; 106(2):312–8. [PubMed: 18791183] 
7. McHale CM, Zhang L, Hubbard AE, et al. Toxicogenomic profiling of chemically exposed humans 
in risk assessment. Mutat Res. 2010; 705(3):172–83. [PubMed: 20382258] 
8. Holsapple MP, Wallace KB. Dose response considerations in risk assessment--an overview of recent 
ILSI activities. Toxicol Lett. 2008; 180(2):85–92. [PubMed: 18588961] 
9. NRC (National Research Council). Biological markers in environmental health research. Environ 
Health Perspect. 1987; 74:3–9. [PubMed: 3691432] 
10. Schulte, PA.; Perera, FP. Validation. In: Schulte, PA.; Perera, FP., editors. Molecular 
Epidemiology: Principles and Practices. San Diego, CA: Academic Press; 1993. 
11. Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature. 2009; 
461(7261):218–23. [PubMed: 19741703] 
12. Aardema MJ, MacGregor JT. Toxicology and genetic toxicology in the new era of 
“toxicogenomics”: impact of “-omics” technologies. Mutat Res. 2002; 499(1):13–25. [PubMed: 
11804602] 
13. Thomas RS, Wesselkamper SC, Wang NC, et al. Temporal concordance between apical and 
transcriptional points of departure for chemical risk assessment. Toxicol Sci. 2013; 134(1):180–94. 
[PubMed: 23596260] 
14. Boogaard PJ, Hays SM, Aylward LL. Human biomonitoring as a pragmatic tool to support health 
risk management of chemicals: examples under the EU REACH programme. Regul Toxicol 
Pharmacol. 2011; 59(1):125–32. [PubMed: 20933039] 
15. Stephens ML. An animal protection perspective on 21st century toxicology. J Toxicol Environ 
Health B Crit Rev. 2010; 13(2–4):291–8. [PubMed: 20574903] 
16. Andersen ME, Krewski D. Toxicity testing in the 21st century: bringing the vision to life. Toxicol 
Sci. 2009; 107(2):324–30. [PubMed: 19074763] 
17. Krewski D, Westphal M, Al-Zoughool M, et al. New directions in toxicity testing. Annu Rev 
Public Health. 2011; 32:161–78. [PubMed: 21219154] 
18. Kavlock RJ, Ankley G, Blancato J, et al. Computational toxicology: a state of the science mini 
review. Toxicol Sci. 2008; 103(1):14–27. [PubMed: 18065772] 
19. Rusyn I, Daston GP. Computational toxicology: realizing the promise of the toxicity testing in the 
21st century. Environ Health Perspect. 2010; 118(8):1047–50. [PubMed: 20483702] 
20. Reif DM, Martin MT, Tan SW, et al. Endocrine profiling and prioritization of environmental 
chemicals using ToxCast data. Environ Health Perspect. 2010; 118(12):1714–20. [PubMed: 
20826373] 
21. Judson RS, Kavlock RJ, Setzer RW, et al. Estimating toxicity-related biological pathway altering 
doses for high-throughput chemical risk assessment. Chem Res Toxicol. 2011; 24(4):451–62. 
[PubMed: 21384849] 
22. Thomas RS, Clewell HJ III, Allen BC, et al. Application of transcriptional benchmark dose values 
in quantitative cancer and noncancer risk assessment. Toxicol Sci. 2011; 120(1):194–205. 
[PubMed: 21097997] 
23. Shah I, Wambaugh J. Virtual tissues in toxicology. J Toxicol Environ Health B Crit Rev. 2010; 
13(2–4):314–28. [PubMed: 20574905] 
24. Zhang Q, Bhattacharya S, Andersen ME, et al. Computational systems biology and dose-response 
modeling in relation to new directions in toxicity testing. J Toxicol Environ Health B Crit Rev. 
2010; 13(2–4):253–76. [PubMed: 20574901] 
25. Ruiz P, Mumtaz M, Osterloh J, et al. Interpreting NHANES biomonitoring data, cadmium. Toxicol 
Lett. 2010; 198(1):44–8. [PubMed: 20447450] 
DeBord et al. Page 14













26. Fowler, BA. Biomarkers in Toxicology and Risk Assessment. In: Luch, A., editor. Molecular, 
Clinical and Environmental Toxicology. Heidelberg, Germany: Springer Basel AG; 2012. p. 
459-70.
27. Fowler, BA. Computational Toxicology: Applications for Risk Assessment. Amsterdam, The 
Netherlands: Elsevier Publishers; 2013. 
28. NRC (National Research Council). Science and Decisions: Advancing Risk Assessment. 
Washington, D.C: The National Academies Press; 2009. 
29. Cote I, Anastas PT, Birnbaum LS, et al. Advancing the next generation of health risk assessment. 
Environ Health Perspect. 2012; 120(11):1499–502. [PubMed: 22875311] 
30. Dix DJ, Houck KA, Martin MT, et al. The ToxCast program for prioritizing toxicity testing of 
environmental chemicals. Toxicol Sci. 2007; 95(1):5–12. [PubMed: 16963515] 
31. Casciano DA, Woodcock J. Empowering microarrays in the regulatory setting. Nat Biotechnol. 
2006; 24(9):1103. [PubMed: 16964221] 
32. Fostel JM. Future of toxicogenomics and safety signatures: balancing public access to data with 
proprietary drug discovery. Pharmacogenomics. 2007; 8(5):425–30. [PubMed: 17465705] 
33. Brown PO, Botstein D. Exploring the new world of the genome with DNA microarrays. Nat Genet. 
1999; 21(1 Suppl):33–7. [PubMed: 9915498] 
34. Thomas RS, Allen BC, Nong A, et al. A method to integrate benchmark dose estimates with 
genomic data to assess the functional effects of chemical exposure. Toxicol Sci. 2007; 98(1):240–
8. [PubMed: 17449896] 
35. Aylward LL, Hays SM. Biomonitoring-based risk assessment for hexabromocyclododecane 
(HBCD). International journal of hygiene and environmental health. 2011; 214(3):179–87. 
[PubMed: 21440498] 
36. Fukushige S, Horii A. DNA methylation in cancer: a gene silencing mechanism and the clinical 
potential of its biomarkers. Tohoku J Exp Med. 2013; 229(3):173–85. [PubMed: 23419314] 
37. Wild CP. Complementing the genome with an “exposome”: the outstanding challenge of 
environmental exposure measurement in molecular epidemiology. Cancer Epidemiol Biomarkers 
Prev. 2005; 14(8):1847–50. [PubMed: 16103423] 
38. Lesko LJ, Atkinson AJ Jr. Use of biomarkers and surrogate endpoints in drug development and 
regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol. 2001; 
41:347–66. [PubMed: 11264461] 
39. Mittal S, Shah AK, Barkmeier DT, et al. Systems biology of human epilepsy applied to patients 
with brain tumors. Epilepsia. 2013; 54 (Suppl 9):35–9. [PubMed: 24328870] 
40. Lusis AJ, Attie AD, Reue K. Metabolic syndrome: from epidemiology to systems biology. Nat Rev 
Genet. 2008; 9(11):819–30. [PubMed: 18852695] 
41. Wang T, Garcia JG, Zhang W. Epigenetic regulation in particulate matter-mediated 
cardiopulmonary toxicities: a systems biology perspective. Curr Pharmacogenomics Person Med. 
2012; 10(4):314–21. [PubMed: 23185213] 
42. Gangwal S, Brown JS, Wang A, et al. Informing selection of nanomaterial concentrations for 
ToxCast in vitro testing based on occupational exposure potential. Environ Health Perspect. 2011; 
119(11):1539–46. [PubMed: 21788197] 
43. Oberdörster G. Nanotoxicology: in vitro-in vivo dosimetry. Environ Health Perspect. 2012; 
120(1):A13. author reply A. [PubMed: 22214547] 
44. Donaldson K, Borm PJ, Oberdorster G, et al. Concordance between in vitro and in vivo dosimetry 
in the proinflammatory effects of low-toxicity, low-solubility particles: the key role of the 
proximal alveolar region. Inhal Toxicol. 2008; 20(1):53–62. [PubMed: 18236223] 
45. Rushton EK, Jiang J, Leonard SS, et al. Concept of assessing nanoparticle hazards considering 
nanoparticle dosemetric and chemical/biological response metrics. J Toxicol Environ Health A. 
2010; 73(5):445–61. [PubMed: 20155585] 
46. American Conference of Governmental Industrial Hygienists (ACGIH). [Accessed January 6, 
2014] TLV/BEI Resources. (http://www.acgih.org/TLV/)
47. Hays SM, Aylward LL, LaKind JS, et al. Guidelines for the derivation of Biomonitoring 
Equivalents: report from the Biomonitoring Equivalents Expert Workshop. Regul Toxicol 
Pharmacol. 2008; 51(3 Suppl):S4–S15. [PubMed: 18583008] 
DeBord et al. Page 15













48. Crump KS. A new method for determining allowable daily intakes. Fundam Appl Toxicol. 1984; 
4(5):854–71. [PubMed: 6510615] 
49. Crump KS. Calculation of benchmark doses from continuous data. Risk Anal. 1995; 15(1):79–89.
50. U.S. Environmental Protection Agency. [Accessed January 6, 2014] Benchmark Dose Technical 
Guidance. 2012. (http://www.epa.gov/raf/publications/pdfs/benchmark_dose_guidance.pdf)
51. Lohmueller KE, Pearce CL, Pike M, et al. Meta-analysis of genetic association studies supports a 
contribution of common variants to susceptibility to common disease. Nat Genet. 2003; 33(2):
177–82. [PubMed: 12524541] 
52. Demchuk E, Yucesoy B, Johnson VJ, et al. A statistical model for assessing genetic susceptibility 
as a risk factor in multifactorial diseases: lessons from occupational asthma. Environ Health 
Perspect. 2007; 115(2):231–4. [PubMed: 17384770] 
53. Scinicariello F, Yesupriya A, Chang MH, et al. Modification by ALAD of the association between 
blood lead and blood pressure in the U.S. population: results from the Third National Health and 
Nutrition Examination Survey. Environ Health Perspect. 2010; 118(2):259–64. [PubMed: 
20123609] 
54. Renwick AG, Lazarus NR. Human variability and noncancer risk assessment: an analysis of the 
default uncertainty factor. Regul Toxicol Pharmacol. 1998; 27(1):3–20.
55. U.S. Environmental Protection Agency. [Accessed January 6, 2014] A Review of The Reference 
Dose and Reference Concentration Processes. 2002. (http://www.epa.gov/raf/publications/pdfs/
rfd-final.pdf)
56. Dourson M, Charnley G, Scheuplein R. Differential sensitivity of children and adults to chemical 
toxicity. II. Risk and regulation. Regul Toxicol Pharmacol. 2002; 35(3):448–67. [PubMed: 
12202058] 
57. IPCS (International Programme on Chemical Safety). [Accessed January 7, 2014] Harmonization 
Project Document No. 2: Chemical-Specific Adjustment Factors for Interspecies Differences and 
Human Variability: Guidance Document for Use of Data in Dose/Concentration-Response 
Assessment. 2005. (http://whqlibdoc.who.int/publications/2005/9241546786_eng.pdf)
58. Samet JM, Schnatter R, Gibb H. Epidemiology and risk assessment. Am J Epidemiol. 1998; 
148(10):929–36. [PubMed: 9829864] 
59. Stayner LT, Smith RJ. Methodologic issues in using epidemiologic studies of occupational cohorts 
for cancer risk assessment. Epidemiol Prev. 1992; 14(53):32–9. [PubMed: 1341666] 
60. Bogdanffy MS, Daston G, Faustman EM, et al. Harmonization of cancer and noncancer risk 
assessment: proceedings of a consensus-building workshop. Toxicol Sci. 2001; 61(1):18–31. 
[PubMed: 11294970] 
61. U.S. Environmental Protection Agency. Guidelines for Carcinogen Risk Assessment. Washington, 
D.C: U.S. Environmental Protection Agency; 2005. publication no. Report #EPA/630/P-03/001b)
62. Boobis AR, Doe JE, Heinrich-Hirsch B, et al. IPCS framework for analyzing the relevance of a 
noncancer mode of action for humans. Crit Rev Toxicol. 2008; 38(2):87–96. [PubMed: 18259981] 
63. Haber, LT.; Strawson, JE.; Maier, AM., et al. Noncancer Risk Assessment: Principles and Practice 
in Environmental and Occupational Settings. In: Bingham, E.; Cohrssen, B., editors. Patty’s 
Toxicology. New York: John Wiley & Sons, Inc; 2012. p. 89-132.
64. U.S. Department of Health and Human Services. Current Intelligence Bulletin 63: Occupational 
Exposure to Titanium Dioxide. Cincinnati, OH: Centers for Disease Control and Prevention, 
National Institute for Occupational Safety and Health; 2011. (Rice F publication no. 2011–160)
65. White RH, Cote I, Zeise L, et al. State-of-the-science workshop report: issues and approaches in 
low-dose-response extrapolation for environmental health risk assessment. Environ Health 
Perspect. 2009; 117(2):283–7. [PubMed: 19270800] 
66. Rhomberg LR, Goodman JE, Haber LT, et al. Linear low-dose extrapolation for noncancer heath 
effects is the exception, not the rule. Crit Rev Toxicol. 2011; 41(1):1–19. [PubMed: 21226629] 
67. Crump KS, Hoel DG, Langley CH, et al. Fundamental carcinogenic processes and their 
implications for low dose risk assessment. Cancer Res. 1976; 36(9 pt 1):2973–9. [PubMed: 
975067] 
DeBord et al. Page 16













68. Lutz WK. Susceptibility differences in chemical carcinogenesis linearize the dose-response 
relationship: threshold doses can be defined only for individuals. Mutat Res. 2001; 482(1–2):71–6. 
[PubMed: 11535250] 
69. Jarabek AM. Considerations of temporal toxicity challenges current default assumptions. Inhal 
Toxicol. 1995; 7:927–46.
70. Kalberlah F, Föst U, Schneider K. Time extrapolation and interspecies extrapolation for locally 
acting substances in case of limited toxicological data. Ann Occup Hyg. 2002; 46(2):175–85. 
[PubMed: 12074027] 
71. Allen, B.; Maier, AM.; Willis, A., et al. Use of Early Effect Biomarker Data to Enhance Dose-
Response Models of Lung Tumors in Rats Exposed to Titanium Dioxide. Cincinnati, OH: 
Toxicology Excellence for Risk Assessment (TERA); 2013. (http://www.tera.org/Publications/
Publications.html) [Accessed January 6, 2014]
72. Maier A, Savage RE Jr, Haber LT. Assessing biomarker use in risk assessment--a survey of 
practitioners. J Toxicol Environ Health A. 2004; 67(8–10):687–95. [PubMed: 15192862] 
73. Kerr MK, Churchill GA. Statistical design and the analysis of gene expression microarray data. 
Genet Res. 2001; 77(2):123–8. [PubMed: 11355567] 
74. Stekel, D. Microarray Bioinformatics. Cambridge, U.K: Cambridge University Press; 2003. 
75. Yang L, Allen BC, Thomas RS. BMDExpress: a software tool for the benchmark dose analyses of 
genomic data. BMC Genomics. 2007; 8:387. [PubMed: 17961223] 
76. Filipsson AF, Sand S, Nilsson J, et al. The benchmark dose method--review of available models, 
and recommendations for application in health risk assessment. Crit Rev Toxicol. 2003; 33(5):
505–42. [PubMed: 14594105] 
77. Kanehisa M, Goto S, Furumichi M, et al. KEGG for representation and analysis of molecular 
networks involving diseases and drugs. Nucleic Acids Res. 2010; 38(Database issue):D355–60. 
[PubMed: 19880382] 
78. Bureeva S, Nikolsky Y. Quantitative knowledge-based analysis in compound safety assessment. 
Expert Opin Drug Metab Toxicol. 2011; 7(3):287–98. [PubMed: 21254873] 
79. Thomas RS, Black MB, Li L, et al. A comprehensive statistical analysis of predicting in vivo 
hazard using high-throughput in vitro screening. Toxicol Sci. 2012; 128(2):398–417. [PubMed: 
22543276] 
80. Katabami M, Dosaka-Akita H, Honma K, et al. Pneumoconiosis-related lung cancers: preferential 
occurrence from diffuse interstitial fibrosis-type pneumoconiosis. Am J Respir Crit Care Med. 
2000; 162(1):295–300. [PubMed: 10903257] 
81. Schins RP, Knaapen AM. Genotoxicity of poorly soluble particles. Inhal Toxicol. 2007; 19 (Suppl 
1):189–98. [PubMed: 17886067] 
82. Driscoll KE, Deyo LC, Carter JM, et al. Effects of particle exposure and particle-elicited 
inflammatory cells on mutation in rat alveolar epithelial cells. Carcinogenesis. 1997; 18(2):423–
30. [PubMed: 9054638] 
83. Kuempel ED, Smith RJ, Dankovic DA, et al. Rat- and human-based risk estimates of lung cancer 
from occupational exposure to poorly-soluble particles: a quantitative evaluation. J Phys 
Conference Series. 2009; 151:1–12.
84. Conolly RB. The use of biologically based modeling in risk assessment. Toxicology. 2002; 181–
182:275–9.
85. Hattis D, Banati P, Goble R. Distributions of individual susceptibility among humans for toxic 
effects. How much protection does the traditional tenfold factor provide for what fraction of which 
kinds of chemicals and effects? Ann N Y Acad Sci. 1999; 895:286–316. [PubMed: 10676424] 
86. Hattis D, Silver K. Human interindividual variability--a major source of uncertainty in assessing 
risks for noncancer health effects. Risk Anal. 1994; 14(4):421–31. [PubMed: 7972952] 
87. Crump KS, Chen C, Chiu WA, et al. What role for biologically based dose: response models in 
estimating low-dose risk? Environ Health Perspect. 2010; 118(5):585–8. [PubMed: 20056564] 
88. IPCS (International Programme on Chemical Safety). [Accessed January 7, 2014] Characterization 
and Application of Physiologically Based Pharmacokinetic Models in Risk Assessment. 2010. 
(http://www.who.int/ipcs/methods/harmonization/areas/pbpk_models.pdf)
DeBord et al. Page 17













89. Hack CE, Haber LT, Maier A, et al. A Bayesian network model for biomarker-based dose 
response. Risk Anal. 2010; 30(7):1037–51. [PubMed: 20412521] 
90. Budinsky RA, LeCluyse EL, Ferguson SS, et al. Human and rat primary hepatocyte CYP1A1 and 
1A2 induction with 2,3,7,8-tetrachlorodibenzo-p-dioxin, 2,3,7,8-tetrachlorodibenzofuran, and 
2,3,4,7,8-pentachlorodibenzofuran. Toxicol Sci. 2010; 118(1):224–35. [PubMed: 20705892] 
91. Black MB, Budinsky RA, Dombkowski A, et al. Cross-species comparisons of transcriptomic 
alterations in human and rat primary hepatocytes exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. 
Toxicol Sci. 2012; 127(1):199–215. [PubMed: 22298810] 
92. Dourson M, Hertzberg R, Allen B, et al. Evidence-based dose-response assessment for thyroid 
tumorigenesis from acrylamide. Regul Toxicol Pharmacol. 2008; 52(3):264–89. [PubMed: 
18775759] 
93. Demchuk E, Ruiz P, Chou S, et al. SAR/QSAR methods in public health practice. Toxicol Appl 
Pharmacol. 2011; 254(2):192–7. [PubMed: 21034766] 
94. Andersen ME, Dennison JE, Thomas RS, et al. New directions in incidence-dose modeling. Trends 
Biotechnol. 2005; 23(3):122–7. [PubMed: 15734554] 
95. Woodruff T, Wells E, Holt E, et al. Estimating risk from ambient concentrations of acrolein across 
the United States. Environmental Health Perspectives. 2007; 115(3):410–5. [PubMed: 17431491] 
96. U.S. Environmental Protection Agency. [Accessed January 7, 2014] Terminology Services. 2012. 
(http://ofmpub.epa.gov/sor_internet/registry/termreg/home/overview/home.do)
97. NRC (National Research Council). Human biomonitoring for environmental chemicals. 
Washington, D.C: The National Academies Press; 2006. 
98. Collins FB, Vaidya VS. Novel technologies for the discovery and quantitation of biomarkers of 
toxicity. Toxicology. 2008; 245:167–74. [PubMed: 18237837] 
99. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM. Metabolomics: a global biochemical approach 
to drug response and disease. Annu Rev Pharmacol Toxicol. 2008; 48:653–83. [PubMed: 
18184107] 
100. Wishart DS. Applications of metabolomics in drug discovery and development. Drugs in R&D. 
2008; 9(5):307–22. [PubMed: 18721000] 
101. U.S. Environmental Protection Agency. [Accessed January 7, 2014] Advancing the Next 
Generation (NexGen) of Risk Assessment. 2013. (http://www.epa.gov/risk/nexgen/)
102. World Health Organization (WHO). [Accessed January 17, 2014] Environmental Health Criteria 
222: Biomarkers in Risk Assessment: Validity and Validation. 2001. (http://www.inchem.org/
documents/ehc/ehc/ehc222.htm)
103. U.S. Environmental Protection Agency. Methods for Derivation of Inhalation Reference 
Concentrations and Application of Inhalation Dosimetry. Research Triangle Park, NC: U.S. 
Environmental Protection Agency; 1994. publication no. Report #EPA/600/8–90/066F)
DeBord et al. Page 18














Continuum from exposure to disease. Adapted from NRC(9); Schulte and Perera(10)). 
Reprinted with permission from Environmental Health Perspectives
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Biologic responses as a result of an exposure. The intersection results in perturbation of 
biologic pathways. When perturbations are sufficiently large or when the host is unable to 
adapt because of underlying nutritional, genetic, disease, or life-stage status, biologic 
function is compromised, and this leads to toxicity and disease.(94) Reprinted with 
permission from Trends in Biotechnology.
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Frequency distribution of a biomarker (physiological parameter) in two hypothetical 
populations to illustrate the effect of exposure and susceptibility factors. Adapted from 
Woodruff et al. (95). Reprinted with permission from Environmental Health Perspectives.
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Table I
Glossary of key terms
Key Term Definition
Benchmark dose A dose of a substance that when absorbed produces a predetermined change in the response rate of an 
adverse effect relative to the background response rate of this effect
Benchmark response (BMR) A predetermined change in the response rate of an adverse effect relative to the background response rate 
of this effect. The BMR is the basis for deriving benchmark doses.(50)
Biological-based dose response 
models (BBDR)
A predictive model that describes biological processes at the cellular and molecular level linking the target 
organ dose to the adverse effect.(96)
Biomarkers internal measures or markers of exposures or effects for a chemical or agent in the body
Biomarkers of exposure The chemical or its metabolite or the product of an interaction between a chemical and some target 
molecule or cell that is measured in a compartment in an organism(97)
Biomarker of effect A measurable biochemical, physiologic, behavioral, or other alteration in an organism that, depending on 
the magnitude, can be recognized as associated with an established or possible health impairment or 
disease(97)
Biomarker of susceptibility An indicator of an inherent or acquired ability of an organism to respond to the challenge of exposure to a 
specific chemical substance.(97)
Computational Toxicology Computational toxicology identifies trends and patterns in biomarker and chemistry datasets.(19)
Genomics Refers to the entire genome of an organism whereas genetics is the study of a specific gene
Exposome Concept by Wild(37) defined as the totality of exposure over a life time beginning in utero until death and 
the impact those exposures have on health
High throughput screening (HTS) Experiments that can be automated and rapidly performed to measure the effect of substances on a 
biologic process of interest. These assays can evaluate hundreds to many thousands of chemicals over a 
wide concentration range to identify chemical actions on gene, pathway, and cell function
Lowest observed adverse effect 
level (LOAEL)
The lowest exposure level at which there are biologically significant increases in frequency or severity of 
adverse effects between the exposed population and its appropriate control group(96)
Metabolomics Studies the metabolic products of the human body and provides a comprehensive view of cellular 
metabolic changes in small molecules and byproducts.(98) The metabolomics-driven approaches may 
provide insight into complex biochemical processes and the MOA and toxicity of chemicals.(99, 100)
No observed adverse effect level 
(NOAEL)
The highest exposure level at which there are no biologically significant increases in the frequency or 
severity of adverse effects between the exposed population and its appropriate control; some effects may 
be produced at this dose level, but they are not considered adverse or precursors of adverse effects(96)
-omics technology The collective characterization of components and measurement of molecules from a biological field of 
study, which involves large scale data acquisition system that can be used to measure biological states or 
responses. Examples include genomics, proteomics, transcriptomics, and toxicogenomics
Proteomics Involves the identification, characterization, and quantitation of expressed proteins in biological samples. 
Provides complementary functional information to genomics
Systems biology An approach used to integrate biological data to understand how biological systems function
Toxicogenomics Brings together toxicology, genetics, and molecular biology such as transcriptomics, proteomics, and 
environmental health to understand the response of an organism to an external insult. The promise of this 
technology is that biomarkers of exposure and effect can be elucidated.(7) Insight into the mechanism of 
action and low-dose effects are other benefits
Transcriptomics The study of RNA transcripts that result in gene expression
Uncertainty factors A numerical value (often a factor of 3 or 10) used to adjust a point of departure (e.g., generally a no 
observed/lowest observed adverse effect level or benchmark dose) in order to derive a reference 
concentration or reference dose. Uncertainty factors are applied as needed to account for extrapolation of 
results in experimental animals to humans, inter-individual variability including sensitive subgroups, 
extrapolation from a NOAEL or LOAEL, extrapolation of results from subchronic exposures to chronic 
exposures, and database inadequacies.(101)
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Table II
Definitions of Acronyms
ANOVA Analysis of variance
BMD Benchmark dose
BMDL Benchmark dose and associated lower confidence limit
BBDR Biologically-Based Dose Response
EPA Environmental Protection Agency
FDA Food and Drug Administration
FEL Frank effect level
HTS High throughput screening
LOAEL Lowest observed adverse effect levels
MOA Mode of action
NAS National Academy of Sciences
NIH National Institutes of Health
NIOSH National Institute for Occupational Safety and Health
NOAEL No observed adverse effect level
NOEL No observed effect level
NRC National Research Council
OEL Occupational exposure limit
PBPK Physiological-based pharmacokinetic
REACH Registration, Evaluation, Authorisation, and Restriction of Chemicals
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Table III
Different Types of Biomarkers
Type of Biomarker Characteristics Example
Exposure Measurement that reflects biologically effective and internal dose Urine or blood concentration of agent
Effect Measurable biochemical, physiological, or other alteration that can be 
recognized as a potential health impairment(102)
DNA mutation or cytogenetic change
Susceptibility Inherent or acquired sensitivities or resistance in response to specific 
exposures
Genetic polymorphisms in metabolic 
activation/deactivation enzymes
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Table IV
Efforts Affecting the Use of 21st Century Technologies and Risk Assessment
Group Name Result/Goals
European Commission Registration, Evaluation, Authorisation, 
and Restriction of Chemicals (REACH)
(14)
Determination of risk of chemicals to improve the protection 
of human health and the environment
National Research Council Toxicity Testing in the 21st Century(3) Recommendations for greater use of in vitro testing and 
computational approaches
National Research Council Applications of Toxicogenomic 
Technologies to Predictive Toxicology and 
Risk Assessment(1)
Recommendations for use of toxicogenomic technologies in 
risk assessment
National Academy of Sciences Meeting on Use of Emerging Science for 
Environmental Health Decisions(19)
Discussion of promise of computational toxicology for policy 
decisions
National Research Council Science and Decisions: Advancing Risk 
Assessment(28)
Recommendations for improvements in the science and 
practice of risk assessment
EPA NexGen(101) Evaluation of use of HTS, computational toxicology and 
systems modeling for risk assessment
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Table V
Uses of Biomarkers in Hazard Characterization and Dose-Response Analysis
Aids in the identification of mode of action in support of risk assessment
Extends the dose-response curve to lower levels of exposure
Addresses uncertainty and variability including interspecies differences and identifying susceptible population
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Table VI
Examples of -Omics Technologies
Technology Parameters
Proteomics Involves the identification, characterization and quantitation of expressed proteins in biological samples. Provides 
complementary functional information to genomics.
Metabolomics Studies the metabolic products of the human body and provides a comprehensive view of cellular metabolic changes in 
small molecules and by-products.(98) The metabolomics-driven approaches may provide insight into complex biochemical 
processes and the MOA and toxicity of chemicals.(99, 100)
Toxicogenomics Brings together toxicology, genetics, and molecular biology such as transcriptomics, proteomics, and environmental health 
to understand the response of an organism to an external insult. The promise of this technology is that biomarkers of 
exposure and effect can be elucidated.(7) Insight into the mechanism of action and low-dose effects are other benefits.
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Table VII
Effect Levels, by Severity, that are Considered in the Derivation of Exposure Limits
Effect or No 
Effect Level
General Effect
NOEL No observed biological effects in the exposed population
NOAEL Effects may be seen at this level but not considered to be adverse
a. Enzyme induction or other biochemical change, consistent with possible mechanism of action, with no 
pathological changes and no change in organ weights
b. Enzyme induction and subcellular proliferation or other changes in organelles, consistent with possible 
mechanism of action, but not other apparent effects.
c. Hyperplasia, hypertrophy, or atrophy, but no changes in organ weights
LOAEL Lowest exposure concentration where adverse effects are seen between the exposed and the control population.
a. Reversible cellular changes including cloudy swelling, hydropic change or fatty changes
b. Degenerative or necrotic tissues with no apparent decrement in organ function
FEL Exposure level in which unmistakable adverse effects are seen that are likely to be irreversible
a. Pathological changes with definite organ dysfunctions
b. Pronounced pathological changes with severe organ dysfunction with long-term sequelae
Notes: NOEL – No Observed Effect Level; NOAEL – No Observed Adverse Effect Level; LOAEL – Lowest Observed Adverse Effect Level; FEL 
– Frank Effect Level. Adapted from EPA(103)
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